The role of glial reaction and inflammation in Parkinson's disease - PubMed (original) (raw)

Review

The role of glial reaction and inflammation in Parkinson's disease

E C Hirsch et al. Ann N Y Acad Sci. 2003 Jun.

Abstract

The glial reaction is generally considered to be a consequence of neuronal death in neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In Parkinson's disease, postmortem examination reveals a loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. Recent evidence suggests that the disease may progress even when the initial cause of neuronal degeneration has disappeared, suggesting that toxic substances released by the glial cells may be involved in the propagation and perpetuation of neuronal degeneration. Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF-alpha, Il-1beta, IFN-gamma), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. In line with this possibility, an activation of proteases such as caspase-3 and caspase-8, which are known effectors of apoptosis, has been reported in Parkinson's disease. Yet, caspase inhibitors or invalidation of TNF-alpha receptors does not protect dopaminergic neurons against degeneration in experimental models of the disease, suggesting that manipulation of a single signaling pathway may not be sufficient to protect dopaminergic neurons. In contrast, the antiinflammatory drugs pioglitazone, a PPAR-gamma agonist, and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease.

PubMed Disclaimer

Cited by

Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease.
Barreto GE, Iarkov A, Moran VE. Barreto GE, et al. Front Aging Neurosci. 2015 Jan 9;6:340. doi: 10.3389/fnagi.2014.00340. eCollection 2014. Front Aging Neurosci. 2015. PMID: 25620929 Free PMC article. Review.
Plant-derived flavanol (-)epicatechin enhances angiogenesis and retention of spatial memory in mice.
van Praag H, Lucero MJ, Yeo GW, Stecker K, Heivand N, Zhao C, Yip E, Afanador M, Schroeter H, Hammerstone J, Gage FH. van Praag H, et al. J Neurosci. 2007 May 30;27(22):5869-78. doi: 10.1523/JNEUROSCI.0914-07.2007. J Neurosci. 2007. PMID: 17537957 Free PMC article.
Endothelin, astrocytes and glaucoma.
Prasanna G, Krishnamoorthy R, Yorio T. Prasanna G, et al. Exp Eye Res. 2011 Aug;93(2):170-7. doi: 10.1016/j.exer.2010.09.006. Epub 2010 Sep 16. Exp Eye Res. 2011. PMID: 20849847 Free PMC article. Review.
Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
Itoh T, Yamamoto K. Itoh T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):541-7. doi: 10.1007/s00210-007-0251-x. Epub 2008 Jan 8. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18193404 Review.
Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinson's disease.
Rahman MM, Chakraborti RR, Potol MA, Abir AH, Sharmin O, Alam M, Khan MFR, Afrin R, Jannat H, Wadud R, Habib ZF. Rahman MM, et al. Animal Model Exp Med. 2019 Dec 30;3(1):9-21. doi: 10.1002/ame2.12097. eCollection 2020 Mar. Animal Model Exp Med. 2019. PMID: 32318655 Free PMC article.

The role of glial reaction and inflammation in Parkinson's disease - PubMed (original) (raw)